JP2023164918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023164918A5 JP2023164918A5 JP2023142246A JP2023142246A JP2023164918A5 JP 2023164918 A5 JP2023164918 A5 JP 2023164918A5 JP 2023142246 A JP2023142246 A JP 2023142246A JP 2023142246 A JP2023142246 A JP 2023142246A JP 2023164918 A5 JP2023164918 A5 JP 2023164918A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- optionally substituted
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 165
- 125000001072 heteroaryl group Chemical group 0.000 claims description 80
- 125000003118 aryl group Chemical group 0.000 claims description 69
- 150000001875 compounds Chemical class 0.000 claims description 69
- 125000003545 alkoxy group Chemical group 0.000 claims description 63
- 229910052736 halogen Inorganic materials 0.000 claims description 63
- 150000002367 halogens Chemical class 0.000 claims description 61
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 56
- 125000003342 alkenyl group Chemical group 0.000 claims description 52
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 52
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 50
- 125000001188 haloalkyl group Chemical group 0.000 claims description 45
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 41
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000000304 alkynyl group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- -1 -NH 2 Chemical group 0.000 claims description 20
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 101150020913 USP7 gene Proteins 0.000 claims description 7
- 102000052151 Ubiquitin-Specific Peptidase 7 Human genes 0.000 claims description 7
- 108700011958 Ubiquitin-Specific Peptidase 7 Proteins 0.000 claims description 7
- 229940126752 Ubiquitin-specific protease 7 inhibitor Drugs 0.000 claims description 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229940125782 compound 2 Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563375P | 2017-09-26 | 2017-09-26 | |
| US62/563,375 | 2017-09-26 | ||
| PCT/US2018/052797 WO2019067503A1 (en) | 2017-09-26 | 2018-09-26 | NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| JP2020515000A JP7402792B2 (ja) | 2017-09-26 | 2018-09-26 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515000A Division JP7402792B2 (ja) | 2017-09-26 | 2018-09-26 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023164918A JP2023164918A (ja) | 2023-11-14 |
| JP2023164918A5 true JP2023164918A5 (enExample) | 2024-11-14 |
Family
ID=65903565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515000A Active JP7402792B2 (ja) | 2017-09-26 | 2018-09-26 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
| JP2023142246A Pending JP2023164918A (ja) | 2017-09-26 | 2023-09-01 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515000A Active JP7402792B2 (ja) | 2017-09-26 | 2018-09-26 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11465983B2 (enExample) |
| EP (1) | EP3687537A4 (enExample) |
| JP (2) | JP7402792B2 (enExample) |
| AU (1) | AU2018342089B2 (enExample) |
| CA (1) | CA3072353A1 (enExample) |
| WO (1) | WO2019067503A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7402792B2 (ja) | 2017-09-26 | 2023-12-21 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
| CA3113547A1 (en) * | 2018-10-22 | 2020-04-30 | Dana-Farber Cancer Institute, Inc. | Usp7 inhibition |
| SG11202105911PA (en) * | 2018-12-06 | 2021-07-29 | Almac Discovery Ltd | Usp19 inhibitors for use in therapy |
| CN114401715A (zh) * | 2019-05-06 | 2022-04-26 | 瓦洛健康股份有限公司 | 抑制usp19 |
| CA3167473A1 (en) | 2020-02-28 | 2021-09-02 | Immunologik Gmbh | Inhibitors of human deubiquitinases for the treatment of coronaviral infections |
| CN112047933B (zh) * | 2020-10-15 | 2022-06-14 | 郑州大学 | 喹唑啉酮类usp7抑制剂及其制备方法和应用 |
| GB202104097D0 (en) * | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3344099A (en) * | 1998-04-17 | 1999-11-08 | Kyowa Hakko Kogyo Co. Ltd. | Analgetic agent |
| ES2347544T3 (es) | 2002-03-13 | 2010-11-02 | Janssen Pharmaceutica Nv | Inhibidores de histona-desacetilasas. |
| DK2044026T3 (da) | 2006-06-22 | 2014-06-30 | Prana Biotechnology Ltd | Fremgangsmde til behandling af cerebral glioma tumor |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| HK1248220A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 |
| HK1248221A1 (zh) * | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| WO2016126929A1 (en) * | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| GB201612938D0 (en) | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| JP7402792B2 (ja) | 2017-09-26 | 2023-12-21 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
| CA3113547A1 (en) | 2018-10-22 | 2020-04-30 | Dana-Farber Cancer Institute, Inc. | Usp7 inhibition |
-
2018
- 2018-09-26 JP JP2020515000A patent/JP7402792B2/ja active Active
- 2018-09-26 WO PCT/US2018/052797 patent/WO2019067503A1/en not_active Ceased
- 2018-09-26 CA CA3072353A patent/CA3072353A1/en active Pending
- 2018-09-26 AU AU2018342089A patent/AU2018342089B2/en active Active
- 2018-09-26 US US16/650,727 patent/US11465983B2/en active Active
- 2018-09-26 EP EP18862773.1A patent/EP3687537A4/en active Pending
-
2022
- 2022-09-02 US US17/902,512 patent/US20230265070A1/en active Pending
-
2023
- 2023-09-01 JP JP2023142246A patent/JP2023164918A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023164918A5 (enExample) | ||
| JP2020535124A5 (enExample) | ||
| AU2014222641B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B | |
| JP2016500107A5 (ja) | グルタミナーゼ阻害剤およびその使用方法 | |
| JP2020528889A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| JP2019529490A5 (enExample) | ||
| JP2019507130A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JPWO2019212990A5 (enExample) | ||
| JP2017504653A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| JP2011527686A5 (enExample) | ||
| JP2009511490A5 (enExample) | ||
| JP2008504301A5 (enExample) | ||
| JP2014520108A5 (enExample) | ||
| JPWO2020123827A5 (enExample) | ||
| JP2008504304A5 (enExample) | ||
| JP2019510082A5 (enExample) | ||
| JP2018500351A5 (enExample) | ||
| JPWO2019067503A5 (enExample) | ||
| JP2020518571A5 (enExample) | ||
| JPWO2020102096A5 (enExample) | ||
| JPWO2021055295A5 (enExample) | ||
| JPWO2022251502A5 (enExample) |